Multi-targeting of K-Ras domains and mutations by peptide and small molecule inhibitors

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Activating mutations in K-Ras are linked to aggressive tumor progression and metastasis in cancers like pancreatic cancer.
• Targeting mutant K-Ras has proven challenging despite extensive research efforts.

Purpose of the Study:

• To develop a novel therapeutic strategy by combining small peptide and small molecule inhibitors to target oncogenic K-Ras mutations.
• To investigate the efficacy of this combination therapy against K-Ras mutant tumors.

Main Methods:

• Screening of peptide and small molecule libraries based on K-Ras mutant structural and physicochemical properties.
• Assessing binding affinities and inhibitory effects on tumor cells with K-RasG12D and K-RasG12C mutations.
• Analyzing the impact on K-Ras downstream gene expression (CTNNB1, CCND1).

Main Results:

• Selected peptide and small molecule inhibitors demonstrated significant binding affinities to target sites on mutant K-Ras.
• The combination therapy effectively hindered the growth of tumor cells harboring K-RasG12D and K-RasG12C mutations.
• Downstream gene expression of K-Ras was significantly reduced in treated cells.

Conclusions:

• The developed combinational platform shows potential for blocking oncogenic K-Ras, thereby preventing tumor progression and metastasis.
• Further in vitro and in vivo validation is necessary to confirm the efficacy and safety of this approach.